GLA,also named as Melibiase,Agalsidase and Alpha-galactosidase A,belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal,non-reducing alpha-D-galactose residues in alpha-D-galactosides,including galactose oligosaccharides,galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease,a lysosomal storage disease.